25-hydroxyvitamin D levels and survival in advanced pancreatic cancer: Findings from CALGB 80303 (Alliance)

Journal of the National Cancer Institute

Volumn 106, Issue 8, 2014, Pages

  Van Loon, Katherine ^a   Owzar, Kouros ^b,c   Jiang, Chen ^c   Kindler, Hedy L ^d   Mulcahy, Mary F ^e   Niedzwiecki, Donna ^b,c   O'Reilly, Eileen M ^f   Fuchs, Charles ^g   Innocenti, Federico ^h   Venook, Alan P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; BEVACIZUMAB; GEMCITABINE; PLACEBO; 25-HYDROXYVITAMIN D; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VITAMIN D;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASSOCIATION; BLACK PERSON; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CAUCASIAN; FEMALE; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PANCREAS CANCER; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RACE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; AFRICAN AMERICAN; BLOOD; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84907007749     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju185     Document Type: Article

References (45)

1. Jensen SS, Madsen MW, Lukas J, et al. Sensitivity to growth suppression by 1alpha,25-dihydroxyvitamin D(3) among MCF-7 clones correlates with vitamin D receptor protein induction. J Steroid Biochem Mol Biol. 2002;81:123-133.
2. Oades GM, Dredge K, Kirby RS, et al. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int. 2002;90:607-616.
3. Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer. 2002;9:45-59.
4. Palmer HG, Gonzalez-Sancho JM, Espada J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol. 2001;154:369-387.
5. Zugmaier G, Jager R, Grage B, et al. Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer. 1996;73:1341-1346.
6. Pettersson F, Colston KW, Dalgleish AG. Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro. Br J Cancer. 2000;83:239-245.
7. Ohlsson B, Albrechtsson E, Axelson J. Vitamins A and D but not E and K decreased the cell number in human pancreatic cancer cell lines. Scand J Gastroenterol. 2004;39:882-885.
8. Colston KW, James SY, Ofori-Kuragu E, et al. Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br J Cancer. 1997;76:1017-1020.
9. Mouratidis PX, Dalgleish AG, Colston KW. Investigation of the mechanisms by which EB1089 abrogates apoptosis induced by 9-cis retinoic acid in pancreatic cancer cells. Pancreas. 2006;32:93-100.
10. Kawa S, Yoshizawa K, Tokoo M, et al. Inhibitory effect of 220-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines. Gastroenterology. 1996;110:1605-1613.
11. Schwartz GG, Eads D, Rao A, et al. Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis. 2004;25:1015-1026.
12. Albrechtsson E, Jonsson T, Moller S, et al. Vitamin D receptor is expressed in pancreatic cancer cells and a vitamin D3 analogue decreases cell number. Pancreatology. 2003;3:41-46.
13. Bland R, Markovic D, Hills CE, et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol. 2004;89-90:121-125.
14. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001;86:888-894.
15. Genetic Marker in the Vitamin D Receptor Gene Associated with Increased overall Survival for Pancreatic Cancer Patients. Lake Tahoe, NV: AACR Press Releases; June 19, 2012.
16. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the cancer and leukemia group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622.
17. Antoniucci DM, Black DM, Sellmeyer DE. Serum 25-hydroxyvitamin D is unaffected by multiple freeze-thaw cycles. Clin Chem. 2005;51:258-261.
18. Ersfeld DL, Rao DS, Body JJ, et al. Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem. 2004;37:867-874.
19. Wagner D, Hanwell HE, Vieth R. An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem. 2009;42:1549-1556.
20. Holick MF. Vitamin D status: Measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19:73-78.
21. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: John Wiley & Sons; 1973.
22. Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: A conditional inference framework. Journal of Computational and Graphical Statistics. 2006;15:651-674.
23. Innocenti F, Owzar K, Cox NL, et al. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012;18:577-584.
24. Jung SH, Owzar K, George SL. A multiple testing procedure to associate gene expression levels with survival. Statistics in Medicine. 2005;24:3077.
25. Pearson K. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. Philosophical Magazine Series 5. 1900;50:157-175.
26. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18-28.
27. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. Journal of the Royal Statistical Society, Series A. 1972;135(2):185-207.
28. Cox DR, Oakes D. Analysis of Survival Data. New York, NY: Chapman and Hall; 1984.
29. Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. Journal of the American Statistical Association. 1952;47:583-621.
30. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
31. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, New York: Springer-Verlag; 2000.
32. Breen J. Zipcode: U.S. ZIP Code Database for Geocoding (ed. R package version 1.0). 2012. Available at: http://cran.r-project.org/web/packages/ zipcode/index.html. Accessed May 23, 2013.
33. Gamer M. Package 'irr' (ed. R package version 0.84). 2012. Available at: http://cran.r-project.org/web/packages/irr/irr.pdf. Accessed September 13, 2013.
34. Crew KD, Shane E, Cremers S, et al. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol. 2009;27:2151-2156.
35. Ng K, Sargent DJ, Goldberg RM, et al. Vitamin D status in patients with stage IV colorectal cancer: Findings from intergroup trial N9741. J Clin Oncol. 2011;29:1599-1606.
36. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med. 2009;169:626-632.
37. Bikle DD. Vitamin D: Newly discovered actions require reconsideration of physiologic requirements. Trends Endocrinol Metab. 2010;21:375-384.
38. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer. 2002;94:1867-1875.
39. Nesby-O'Dell S, Scanlon KS, Cogswell ME, et al. Hypovitaminosis D prevalence and determinants among african american and white women of reproductive age: Third national health and nutrition examination survey, 1988-1994. Am J Clin Nutr. 2002;76:187-192.
40. Clemens TL, Adams JS, Henderson SL, et al. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet. 1982;1:74-76.
41. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2010. 2013. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975-2010/. Accessed June 23, 2014.
42. Jinjuvadia R, Jinjuvadia K, Liangpunsakul S. Racial disparities in gastrointestinal cancers-related mortality in the U.S. population. Dig Dis Sci. 2013;58:236-243.
43. Grant WB, Peiris AN. Differences in vitamin D status may account for unexplained disparities in cancer survival rates between african and white americans. Dermatoendocrinol. 2012;4:85-94.
44. Buttigliero C, Monagheddu C, Petroni P, et al. Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: A systematic review. Oncologist. 2011;16:1215-1227.
45. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338:777-783.